Matthias Schneider1, Klaus Krüger. 1. Department of Rheumatology, Düsseldorf University Hospital, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. schneider@rheumanet.org
Abstract
BACKGROUND: 0.5% to 0.8% of all adults suffer from rheumatoid arthritis (RA). The main considerations for persons with new-onset RA are early diagnosis, disease-modifying anti-rheumatic drugs (DMARDs), remission, and interdisciplinary treatment. METHOD: As part of the process of creating a new S3 guideline on the management of early RA and a new S1 guideline on stage-adapted pharmacotherapy for RA, the authors conducted a selective search and review of the literature and specifically updated it to 20 March 2013. RESULTS: In patients presenting with joint inflammation, the diagnosis of RA can be directly confirmed (positive predictive value, 85% to 97%), and its prognosis assessed, on the basis of the following findings: joint examination, acute phase reaction, serology (rheumatoid factor [RF], antibody against citrullinated peptides/proteins [ACPA], and duration of symptoms (ACR/Eular classification criteria, 2010). Early, remission-oriented and adapted treatment with DMARDs ("treating to target") leads to several years of normal bodily function without disability in 40% to 60% of patients. Treatment by an interdisciplinary team promotes the achievement of this goal. The risks associated with this form of treatment are low, with a dropout rate of less than 1 per 100 patient-years. Life-threatening complications are rare. CONCLUSION: Early diagnosis, intervention with DMARDs in the first three months of disease, and the achievement of a remission minimize the adverse sequelae of RA. The sequential introduction of DMARDs, including biological agents in non-responders, as part of a treat-to-target concept optimizes the long-term outcome, as has been demonstrated in clinical trials for periods of up to eight years.
BACKGROUND: 0.5% to 0.8% of all adults suffer from rheumatoid arthritis (RA). The main considerations for persons with new-onset RA are early diagnosis, disease-modifying anti-rheumatic drugs (DMARDs), remission, and interdisciplinary treatment. METHOD: As part of the process of creating a new S3 guideline on the management of early RA and a new S1 guideline on stage-adapted pharmacotherapy for RA, the authors conducted a selective search and review of the literature and specifically updated it to 20 March 2013. RESULTS: In patients presenting with joint inflammation, the diagnosis of RA can be directly confirmed (positive predictive value, 85% to 97%), and its prognosis assessed, on the basis of the following findings: joint examination, acute phase reaction, serology (rheumatoid factor [RF], antibody against citrullinated peptides/proteins [ACPA], and duration of symptoms (ACR/Eular classification criteria, 2010). Early, remission-oriented and adapted treatment with DMARDs ("treating to target") leads to several years of normal bodily function without disability in 40% to 60% of patients. Treatment by an interdisciplinary team promotes the achievement of this goal. The risks associated with this form of treatment are low, with a dropout rate of less than 1 per 100 patient-years. Life-threatening complications are rare. CONCLUSION: Early diagnosis, intervention with DMARDs in the first three months of disease, and the achievement of a remission minimize the adverse sequelae of RA. The sequential introduction of DMARDs, including biological agents in non-responders, as part of a treat-to-target concept optimizes the long-term outcome, as has been demonstrated in clinical trials for periods of up to eight years.
Authors: Joel M Kremer; Mark C Genovese; Grant W Cannon; Jacques R Caldwell; John J Cush; Daniel E Furst; Michael E Luggen; Ed Keystone; Michael H Weisman; William M Bensen; Jeffrey L Kaine; Eric M Ruderman; Patricia Coleman; David L Curtis; Elliot J Kopp; Seth M Kantor; Jonathan Waltuck; Herbert B Lindsley; Joseph A Markenson; Vibeke Strand; Bruce Crawford; Indra Fernando; Karen Simpson; Joan M Bathon Journal: Ann Intern Med Date: 2002-11-05 Impact factor: 25.391
Authors: E Tsakonas; A A Fitzgerald; M A Fitzcharles; A Cividino; J C Thorne; A M'Seffar; L Joseph; C Bombardier; J M Esdaile Journal: J Rheumatol Date: 2000-03 Impact factor: 4.666
Authors: L M Jansen; I E van der Horst-Bruinsma; D van Schaardenburg; P D Bezemer; B A Dijkmans Journal: Ann Rheum Dis Date: 2001-10 Impact factor: 19.103
Authors: Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo Journal: Arthritis Rheum Date: 2002-04
Authors: James R O'Dell; Robert Leff; Gail Paulsen; Claire Haire; Jack Mallek; P James Eckhoff; Ana Fernandez; Kent Blakely; Steven Wees; Julie Stoner; Stephen Hadley; Jeffrey Felt; William Palmer; Paul Waytz; Melvin Churchill; Lynell Klassen; Gerald Moore Journal: Arthritis Rheum Date: 2002-05
Authors: A Schwarting; B Pfeiff; C Amberger; D Pick; M Hesse; M Jendro; J Engels; A Böttger; C Kuhn; J Majdandzic; W Ziese; M-L Stadelmann; F W Kessler; H Dinges; S Ultes-Kaiser; U Droste; M Schmalhofer; A Hazenbiller; M Rector; J Weinmann-Menke; K Triantafyllias; M Becker; M Ataian; M Lablans; F Ueckert; T Panholzer; M Blettner Journal: Z Rheumatol Date: 2016-12 Impact factor: 1.372